Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Andrea Messori, Melania Rivano, Daniele Mengato, Luca Cancanelli, Lorenzo Di Spazio & Marco Chiumente. (2022) A preliminary estimate of survival gain and cost-effectiveness of CAR-T in adult patients with acute lymphoblastic leukemia. Leukemia & Lymphoma 63:5, pages 1261-1264.
Read now
Read now
Ziyan Chen, Yue Cheng, David DeRemer & Vakaramoko Diaby. (2021) Cost-effectiveness and drug wastage of immunotherapeutic agents for hematologic malignancies: a systematic review. Expert Review of Pharmacoeconomics & Outcomes Research 21:5, pages 923-941.
Read now
Read now
Guranda Chitadze, Anna Laqua, Marcus Lettau, Claudia D Baldus & Monika Brüggemann. (2020) Bispecific antibodies in acute lymphoblastic leukemia therapy. Expert Review of Hematology 13:11, pages 1211-1233.
Read now
Read now
Lindsey Hathaway, Jeremy Michael Sen & Michael Keng. (2018) Impact of blinatumomab on patient outcomes in relapsed/refractory acute lymphoblastic leukemia: evidence to date. Patient Related Outcome Measures 9, pages 329-337.
Read now
Read now
Articles from other publishers (15)
Richard T. Maziarz, Steven Devine, Louis P. Garrison, Irene Agodoa, Jack Badaracco, Matthew Gitlin & Miguel-Angel Perales. (2023) Estimating the Lifetime Medical Cost Burden of an Allogeneic Hematopoietic Cell Transplantation Patient. Transplantation and Cellular Therapy 29:10, pages 637.e1-637.e9.
Crossref
Crossref
Caitlyn Duffy, Victor Santana, Hiroto Inaba, Sima Jeha, Jennifer Pauley, Liz Sniderman, Niharendu Ghara, Naureen Mushtaq, Gaurav Narula, Nickhill Bhakta, Carlos Rodriguez-Galindo & Heather Brandt. (2022) Evaluating blinatumomab implementation in low- and middle-income countries: a study protocol. Implementation Science Communications 3:1.
Crossref
Crossref
Shifrin I.A., Blinov Blinov & Karachunskiy A.I.. (2022) APPROPRIATE METHOD FOR FARMACOECONOMIC ANALYSIS OF MONOCLONAL ANTIBODIES EFFICACY IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA. Bulletin "Biomedicine and sociology", pages 13-21.
Crossref
Crossref
Ameet Patel, Olalekan Oluwole, Bipin Savani & Bhagirathbhai Dholaria. (2021) Taking a BiTE out of the CAR T space race. British Journal of Haematology 195:5, pages 689-697.
Crossref
Crossref
Zachery Halford, Carli Coalter, Vanessa Gresham & Tabitha Brown. (2021) A Systematic Review of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Engaging an Old Problem With New Solutions. Annals of Pharmacotherapy 55:10, pages 1236-1253.
Crossref
Crossref
Michael M Boyiadzis, Ivan Aksentijevich, Daniel A Arber, John Barrett, Renier J Brentjens, Jill Brufsky, Jorge Cortes, Marcos De Lima, Stephen J Forman, Ephraim J Fuchs, Linda J Fukas, Steven D Gore, Mark R Litzow, Jeffrey S Miller, John M Pagel, Edmund K Waller & Martin S Tallman. (2020) The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia. Journal for ImmunoTherapy of Cancer 8:2, pages e000810.
Crossref
Crossref
Andreas Viardot, Franco Locatelli, Julia Stieglmaier, Faraz Zaman & Elias Jabbour. (2020) Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies. Annals of Hematology 99:10, pages 2215-2229.
Crossref
Crossref
Tsung-Ying Lee, Hsuan-Ying Chen, Tsai-Yun Chen, Sin-Syue Li, Wei-Tse Fang, Yao-Chun Wen, Yu-Wen Lo & Huang-Tz Ou. (2020) Cost-utility analysis of inotuzumab ozogamicin for relapsed or refractory B cell acute lymphoblastic leukemia from the perspective of Taiwan’s health care system. The European Journal of Health Economics 21:7, pages 1105-1116.
Crossref
Crossref
Maria-Elisabeth Goebeler & Ralf C. Bargou. (2020) T cell-engaging therapies — BiTEs and beyond. Nature Reviews Clinical Oncology 17:7, pages 418-434.
Crossref
Crossref
Dalma Deak, Cristina Pop, Alina-Andreea Zimta, Ancuta Jurj, Alexandra Ghiaur, Sergiu Pasca, Patric Teodorescu, Angela Dascalescu, Ion Antohe, Bogdan Ionescu, Catalin Constantinescu, Anca Onaciu, Raluca Munteanu, Ioana Berindan-Neagoe, Bobe Petrushev, Cristina Turcas, Sabina Iluta, Cristina Selicean, Mihnea Zdrenghea, Alina Tanase, Catalin Danaila, Anca Colita, Andrei Colita, Delia Dima, Daniel Coriu, Hermann Einsele & Ciprian Tomuleasa. (2019) Let’s Talk About BiTEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia. Frontiers in Immunology 10.
Crossref
Crossref
Thomas E. Delea, Xinke Zhang, Jordan Amdahl, Diana Boyko, Franziska Dirnberger, Marco Campioni & Ze Cong. (2019) Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States. PharmacoEconomics 37:9, pages 1177-1193.
Crossref
Crossref
Tania Jain & Mark R. Litzow. (2018) No free rides: management of toxicities of novel immunotherapies in ALL, including financial. Hematology 2018:1, pages 25-34.
Crossref
Crossref
Tania Jain & Mark R. Litzow. (2018) No free rides: management of toxicities of novel immunotherapies in ALL, including financial. Blood Advances 2:22, pages 3393-3403.
Crossref
Crossref
John K. LinBenjamin J. LermanJames I. BarnesBrian C. BoursiquotYuan Jin TanAlex Q.L. RobinsonKara L. DavisDouglas K. OwensJeremy D. Goldhaber-Fiebert. (2018) Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia. Journal of Clinical Oncology 36:32, pages 3192-3202.
Crossref
Crossref
Troy Z. Horvat, Amanda N. Seddon, Adebayo Ogunniyi, Amber C. King, Larry W. Buie & Ryan J. Daley. (2017) The ABCs of Immunotherapy for Adult Patients With B-Cell Acute Lymphoblastic Leukemia. Annals of Pharmacotherapy 52:3, pages 268-276.
Crossref
Crossref